Evidence map›Paper›PMID 41291060›Full record

ArticleScientific reports2025

A comprehensive kinetic model for ternary complex catalysis.

Eugene F Douglass, Chad J Miller

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Eugene F DouglassPharmaceutical and Biomedical Sciences, University of Georgia, 250 W. Green Street, Athens, GA, 30602, USA. eugene.douglass@uga.edu.
Chad J MillerNosis Bio, 1010 Atlantic Ave, Alameda, CA, 94501, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ternary-complex catalysis (TEC) plays a central role in many biological processes and underlies the mechanism of action for a growing class of clinical therapeutics, including growth hormones, interferons, heparin, bispecific antibodies, molecular glues, and PROTACs. Despite its importance, TEC remains conceptually opaque due to the complexity of its multi-body interactions and the lack of a unifying kinetic model. Here, we introduce a general and intuitive kinetic framework for TEC that extends the classic Michaelis–Menten model to ternary systems. By solving for the maximum catalytic rate (Vmax) and revisiting an often-overlooked insight from Michaelis and Menten’s original work – the integration of the velocity equation – we derive equations that are analytically simple yet conceptually powerful. These equations clarify how enzyme concentration, catalytic rate (kcat), and the weakest binding affinity (Kweak) jointly determine the reaction timescale, defined here as the half-life for conversion of the target species to the product under pre-equilibrium conditions. We validate our framework across a wide range of TEC-mediated systems, including heparin-based anticoagulants, PROTAC-mediated protein degradation, and antibody-dependent cell killing. To promote broader accessibility and application, we developed an interactive web-based tool ( https://douglasslab.com/Btmax_kinetics/ ) that allows users to simulate catalytic timescales under real-world conditions using thermodynamic and kinetic datasets. By bridging historical theory with modern therapeutic challenges, this work provides a unifying conceptual lens and practical tools for studying and optimizing TEC-driven biology and drug action.

Identifiers

PMID41291060
PMCPMC12749625

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.